Literature DB >> 21226606

Systems biology of interferon responses.

Paul Hertzog1, Sam Forster, Shamith Samarajiwa.   

Abstract

The interferons (IFNs) are a pleiotropic family of cytokines that perform fundamental functions in protecting host organisms from disease and in maintaining homeostasis. Like other multifunctional cytokines, excessive or inappropriate activity can cause toxicity and even death. Therefore, host organisms have evolved specific and highly regulated mechanisms to control the temporal and tissue specificity of production of IFNs and the selection of pathways and genes to be activated as the effectors of the IFN response in cells. There are now numerous microarray datasets available to enable a "global" analysis of the genes involved in the IFN response. This article describes the INTERFEROME database, which assimilates the available expression profiling data and its contents and enables the definition of IFN-regulated genes, discovery of pathways, regulatory networks, and tissue specificities of the IFN response.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21226606     DOI: 10.1089/jir.2010.0126

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  51 in total

1.  Upregulation of long noncoding RNA TMEVPG1 enhances T helper type 1 cell response in patients with Sjögren syndrome.

Authors:  Juan Wang; Huiyong Peng; Jie Tian; Jie Ma; Xinyi Tang; Ke Rui; Xinyu Tian; Yungang Wang; Jianguo Chen; Liwei Lu; Huaxi Xu; Shengjun Wang
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

Review 2.  Interferon-γ and systemic autoimmunity.

Authors:  Kenneth M Pollard; David M Cauvi; Christopher B Toomey; Kevin V Morris; Dwight H Kono
Journal:  Discov Med       Date:  2013-09       Impact factor: 2.970

Review 3.  Antitumour actions of interferons: implications for cancer therapy.

Authors:  Belinda S Parker; Jai Rautela; Paul J Hertzog
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

4.  Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis.

Authors:  Adrianos Nezos; Fotini Gravani; Anna Tassidou; Efstathia K Kapsogeorgou; Michael Voulgarelis; Michael Koutsilieris; Mary K Crow; Clio P Mavragani
Journal:  J Autoimmun       Date:  2015-07-14       Impact factor: 7.094

Review 5.  Interferons and their stimulated genes in the tumor microenvironment.

Authors:  Hyeonjoo Cheon; Ernest C Borden; George R Stark
Journal:  Semin Oncol       Date:  2014-02-14       Impact factor: 4.929

Review 6.  Too much of a good thing: Detrimental effects of interferon.

Authors:  Nancy C Reich
Journal:  Semin Immunol       Date:  2019-06       Impact factor: 11.130

7.  Elevated interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) is a poor prognostic marker in pancreatic ductal adenocarcinoma.

Authors:  Yue Zhao; Annelore Altendorf-Hofmann; Ioannis Pozios; Peter Camaj; Therese Däberitz; Xiaoyan Wang; Hanno Niess; Hendrik Seeliger; Felix Popp; Christopher Betzler; Utz Settmacher; Karl-Walter Jauch; Christiane Bruns; Thomas Knösel
Journal:  J Cancer Res Clin Oncol       Date:  2017-02-17       Impact factor: 4.553

8.  Transcriptome analysis of the interferon-signature defining the autoimmune process of Sjögren's syndrome.

Authors:  A B Peck; C Q Nguyen
Journal:  Scand J Immunol       Date:  2012-09       Impact factor: 3.487

9.  Elimination of GPR146-mediated antiviral function through IRF3/HES1-signalling pathway.

Authors:  Hongjun Huang; Na Zhang; Qingqing Xiong; Ruoyu Chen; Chengfei Zhang; Ning Wang; Li Wang; Hua Ren; Mingyao Liu; Min Qian; Bing Du
Journal:  Immunology       Date:  2017-06-01       Impact factor: 7.397

10.  Higher activation of the interferon-gamma signaling pathway in systemic lupus erythematosus patients with a high type I IFN score: relation to disease activity.

Authors:  Manman Liu; Junli Liu; Shumeng Hao; Ping Wu; Xiaoyan Zhang; Yichuan Xiao; Gengru Jiang; Xinfang Huang
Journal:  Clin Rheumatol       Date:  2018-05-17       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.